Trials
9 active
11 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.”In the company’s words, NCT06091267 on ClinicalTrials.gov
- Tested for
- Myelodysplastic Syndromes (5 trials), Acute Myeloid Leukemia (4 trials), Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference, Chronic Myelomonocytic Leukemia
- Main trialPhase 3
- “It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic…”In the company’s words, NCT05883956 on ClinicalTrials.gov
- Other names
- cedazuridine + decitabine · INQOVI · DEC-C · Oral decitabine and cedazuridine · Decitabine and Cedazuridine · decitabine/cedazuridine
Other drugs for Myelodysplastic Syndromes
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- MomelotinibSierra Oncology LLC - a GSK company · Phase 2/3
- VenetoclaxAbbVie · Phase 3
Coming up3
- DecPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 6 Dec 2024 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | |
| Phase 2Enrolling by invitation | 31 Dec 2027 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | |
| Phase 1/2Active, not recruiting | 30 Sep 2024 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | |
| Phase 1/2Active, not recruiting | 22 May 2026 | PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | |
| Phase 1Recruiting | Dec 2026 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | |
| Phase 1Recruiting | Dec 2026 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | |
| Phase 1/2Completed | 13 Jan 2026 | Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | |
| Phase 2Authorised | not given | PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF EXPLORATIVE MULTI-OMICS AND EX VIVO DRUG SCREENING DATA | |
| Phase 2Ended | not given | GFM-DACORAL-DLI: ASTX727 and donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (ALLO SCT) in very high-risk MDS or AML patients | |
| Phase 2Authorised | not given | A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 | |
| Phase 2Authorised | not given | A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026